N@N

Sangamo BioSciences Inc. (NASDAQ:SGMO) Up By 14.67% ($0.55) From $3.750 After BUYINS.NET Report Predicted Strength After Earnin

November 10, 2016 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, October 25th 2016 stating that Sangamo BioSciences Inc. (NASDAQ) was expected to be higher After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?id=521082

  Symbol  Company                          # of Reports         Quarter  Release Time
  SGMO    Sangamo BioSciences Inc.         October Earnings     Q3       After

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Sangamo BioSciences Inc. (NASDAQ:SGMO) - Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome modification and gene regulation. The ZFPs could also be linked to a cleavage domain of a restriction endonuclease to create zinc finger nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that could be used to turn genes on or off. Its lead ZFP Therapeutic candidate includes SB-728-T, a ZFN-mediated autologous cell product for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I/II clinical trials. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B and MPS I, a lysosomal storage disorder (LSD); and proprietary preclinical programs in hemophilia A and other LSDs. It has collaborative partnerships with Biogen Inc. (Biogen) to research, develop, and commercialize the preclinical ZFP Therapeutic development program in hemoglobinopathies, including sickle cell disease and beta-thalassemia; and with Shire International GmbH to research, develop, and commercialize the preclinical ZFP Therapeutic development program in Huntington s disease. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---